ContraFect Corp Company Profile (NASDAQ:CFRXU)

Analyst Ratings

Consensus Ratings for ContraFect Corp (NASDAQ:CFRXU) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ContraFect Corp (NASDAQ:CFRXU)
Show:
DateFirmActionRatingPrice TargetActions
10/6/2014Roth CapitalInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2014Maxim GroupInitiated CoverageBuy -> Buy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for ContraFect Corp (NASDAQ:CFRXU)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for ContraFect Corp (NASDAQ:CFRXU)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ContraFect Corp (NASDAQ:CFRXU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ContraFect Corp (NASDAQ:CFRXU)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for ContraFect Corp (NASDAQ:CFRXU)
DateHeadline
01/14/16 10:01 AMContraFect to Present at 27th Annual ROTH Conference - [at noodls] - YONKERS, NY -- (Marketwired) -- 03/03/15 -- ContraFect CorporationJulia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 27th Annual ROTH Conference on Monday, ...
01/14/16 10:01 AMContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results - [at noodls] - ContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results
01/14/16 10:01 AMContraFect Corporation Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA - [at noodls] - Patient Screening Has Begun YONKERS, NY -- (Marketwired) -- 04/29/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development ...
01/14/16 10:01 AMContraFect Corporation Announces First Quarter 2015 Results - [at noodls] - ContraFect Corporation Announces First Quarter 2015 Results
01/14/16 10:01 AMContraFect Corporation Adds Former Cubist Executive Steven C. Gilman, PhD, to Board of Directors as Executive Chairman - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/20/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics ...
01/14/16 10:01 AMContraFect Corporation Announces First Healthy Volunteer Dosed With CF-301 - [at noodls] - YONKERS, NY -- (Marketwired) -- 05/21/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics ...
01/14/16 10:01 AMContraFect Corporation Announces Second Quarter 2015 Financial and Operating Results - [at noodls] - ContraFect Corporation Announces Second Quarter 2015 Financial and Operating Results

Social

About ContraFect Corp

ContraFect Corporation (ContraFect ) is a biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. It intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). Its product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia, and CF-404, a combination of mAbs for the treatment of life-threatening seasonal and pandemic varieties of influenza. CF-301 and CF-302 are bacteriophage lysins with potent activity against Staph aureus infections.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CFRXU
  • CUSIP:
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $N/A
  • 200 Day Moving Average: $N/A
  • P/E Ratio: N/A
  • P/E Growth: N/A
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-3.29 EPS
  • Next Year EPS Consensus Estimate: $-2.00 EPS
Additional Links:
ContraFect Corp (NASDAQ:CFRXU) Chart for Wednesday, July, 27, 2016